Clinical Trials Logo

Takayasu's Arteritis clinical trials

View clinical trials related to Takayasu's Arteritis.

Filter by:

NCT ID: NCT01241305 Recruiting - Clinical trials for Giant Cell Arteritis

One-Time DNA Study for Vasculitis

Start date: October 2010
Phase:
Study type: Observational

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.

NCT ID: NCT00556439 Completed - Clinical trials for Giant Cell Arteritis

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Start date: December 2008
Phase: Phase 2
Study type: Interventional

Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the largest blood vessel in the body, and its branches. Therapies are available to improve the symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed. Abatacept is a drug that interacts with certain cells in the body that are involved with GCA and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and preventing disease relapse.

NCT ID: NCT00315471 Completed - Clinical trials for Takayasu's Arteritis

Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis

Start date: April 2006
Phase:
Study type: Observational

Takayasu's arteritis is a rare disorder that causes swelling and damage to the large arteries in the body, such as the aorta. In order to ensure proper treatment, measuring disease activity is critical. The purpose of this study is to establish new biological markers (biomarkers) to assess the severity of disease in people with Takayasu's arteritis.